SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-β production

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 1, 2013, Pages 272-279

  Meng, Fei ^a   Zhao, Xiaoyun ^b   Zhang, Shulan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cell proliferation; Cervical cancer; SH2 containing protein tyrosine phosphatase 2; Type I interferon

Indexed keywords

BETA INTERFERON; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL GROWTH; CELL INFILTRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERUS MYOMA;

ADULT; CELL LINE, TUMOR; CELL PROLIFERATION; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; INTERFERON-BETA; MIDDLE AGED; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; UTERINE CERVICAL NEOPLASMS;

EID: 84875751967     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2012.01952.x     Document Type: Article

References (27)

1. Einstein MH. Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. Cancer Immunol Immunother 2008; 57: 443-451.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Sittidilokratna K, Cheewakriangkrai C, Khunamornpong S, Siriaunkgul S. Recurrence patterns after radical hysterectomy in stage IB1-IIA cervical. Asian Pac J Cancer Prev 2010; 11: 499-502.
4. Caraglia M, Marra M, Tagliaferri P et al. Emerging strategies to strengthen the anti-Tumour activity of type I interferons: Overcoming survival pathways. Curr Cancer Drug Targets 2009; 9: 690-704.
5. Vannucchi S, Percario ZA, Chiantore MV et al. Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells. Oncogene 2000; 19: 5041-5053.
6. Massad LS, Turyk ME, Bitterman P,Wilbanks GD. Interferonalpha and all-Trans-retinoic acid reversibly inhibit the in vitro proliferation of cell lines derived from cervical cancers. Gynecol Oncol 1996; 60: 428-434.
7. Matarrese P, Giandomenico V, Fiorucci G et al. Antiproliferative activity of interferon alpha and retinoic acid in SiHa carcinoma cells: The role of cell adhesion. Int J Cancer 1998; 76: 531-540.
8. Tsai SY, Hsieh TC, Ardelt B, Darzynkiewicz Z, Wu JM. Combined effects of onconase and IFN-beta on proliferation, macromolecular syntheses and expression of STAT-1 in JCA-1 cancer cells. Int J Oncol 2002; 20: 891-896.
9. Feng GS. Shp-2 tyrosine phosphatase: Signaling one cell or many. Exp Cell Res 1999; 253: 47-54.
10. Salmond RJ, Alexander DR. SHP2 forecast for the immune system: Fog gradually clearing. Trends Immunol 2006; 27: 154-160.
11. Yu WM, Hawley TS, Hawley RG, Qu CK. Catalyticdependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene 2003; 22: 5995-6004.
12. Du Z, Shen Y, Yang W, Mecklenbrauker I, Neel BG, Ivashkiv LB. Inhibition of IFN-Alpha signaling by a PKC-And protein tyrosine phosphatase SHP-2-dependent pathway. Proc Natl Acad Sci U S A 2005; 102: 10267-10272.
13. You M, Yu DH, Feng GS. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/ STAT pathway. Mol Cell Biol 1999; 19: 2416-2424.
14. Hong F, Nguyen VA, Gao B. Tumor necrosis factor alpha attenuates interferon alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB J 2001; 15: 1595-1597.
15. An H, Zhao W, Hou J et al. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity 2006; 25: 919-928.
16. McDonald JS, Gartside PS, Pavelic LJ, Gluckman JL, Pavelic ZP. nm23-H1 expression in squamous cell carcinoma of the head and neck. Pathol Oncol Res 1996; 2: 34-36.
17. Xu R, Yu Y, Zheng S et al. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood 2005; 106: 3142-3149.
18. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domaincontaining tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003; 28: 284-293.
19. CK Q. The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. Cell Res 2000; 10: 279-288.
20. Ke Y, Zhang EE, Hagihara K et al. Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol Cell Biol 2007; 27: 6706-6717.
21. Voena C, Conte C, Ambrogio C et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res 2007; 67: 4278-4286.
22. Xu R. Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia. Cell Res 2007; 17: 295-297.
23. Zhou X, Coad J, Ducatman B, Agazie YM. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology 2008; 53: 389-402.
24. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 2008; 27: 179-192.
25. Tao XH, Shen JG, Pan WL et al. Significance of SHP-1 and SHP-2 expression in human papillomavirus infected Condyloma acuminatum and cervical cancer. Pathol Oncol Res 2008; 14: 365-371.
26. Rui Y, Liu X, Li N et al. PECAM-1 ligation negatively regulates TLR4 signaling in macrophages. J Immunol 2007; 179: 7344-7351.
27. Toshchakov V, Jones BW, Perera PY et al. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/betadependent gene expression in macrophages. Nat Immunol 2002; 3: 392-398.